Results 51 to 60 of about 4,368 (201)

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes [PDF]

, 2022
Objective: Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be mediated primarily via nonhemodynamic pathways, but office blood pressure (BP ...
Bakris, George L., Anker, Stefan D, Nowack, Christina, Kolkhof, Peter, Ruilope, Luis Miguel, Haller, Hermann, Filippatos, Gerasimos, Ruilope, Luis M., Anker, Stefan D., Ruiz-Hurtado, Gema, Lambelet, Marc, Bakris, George L, Agarwal, Rajiv, Schmieder, Roland E, Rossing, Peter, Schmieder, Roland E., Pitt, Bertram, Ruilope, Luis M, Joseph, Amer, Ruiz Hurtado, Gema, Hermann Haller, Gerasimos Filippatos, Amer Joseph, Gema Ruiz-Hurtado, Stefan D. Anker, Roland E. Schmieder, Rajiv Agarwal, George L Bakris, Peter Rossing, Luis M. Ruilope, Bertram Pitt, Peter Kolkhof, Marc Lambelet, Christina Nowack   +33 more
core   +1 more source

Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease

Metabolism Open
Introduction: Diabetic kidney disease (DKD) is an important complication of diabetes as it results in end-stage renal disease; hence, several drugs have been developed for its treatment.
Akira Mima, Yuta Saito, Keishi Matsumoto, Takahiro Nakamoto, Shinji Lee   +4 more
doaj   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.

, 2023
BACKGROUND: In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces cardiovascular and kidney failure outcomes.
Farjat, Alfredo E, Tu, Wanzhu, Rohwedder, Katja, Anker, Stefan D, Kaul, Sanjay, Lawatscheck, Robert, Farag, Youssef M K, Filippatos, Gerasimos, Toto, Robert, Bakris, George L, Agarwal, Rajiv, Kopyt, Nelson, DO, FASN, FACP, Rossing, Peter, Pitt, Bertram, Ruilope, Luis M   +14 more
core   +3 more sources

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Cardiovascular Diabetology, 2022
Objective To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney ...
Yaofu Zhang, Li Jiang, Junheng Wang, Tongxin Wang, Chieh Chien, Weijun Huang, Xiaozhe Fu, Yonghua Xiao, Qiang Fu, Shidong Wang, Jinxi Zhao   +10 more
doaj   +1 more source

Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis

Scientific Reports
Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant efficacy in the management of myocardial infarction (MI).
Yebao Wang, Junyi Zhang, Feng Lv, Ting Zhang, Yafeng Zhou   +4 more
doaj   +1 more source

Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis

Frontiers in Pharmacology
BackgroundSodium-glucose cotransporter two inhibitors (SGLT2is) and finerenone have demonstrated individual efficacy in reducing cardiorenal events among patients with diabetic chronic kidney disease (CKD).
Chen-Fu Wen, Min-Hsiang Chuang, Vin-Cent Wu, Jui-Yi Chen, Jui-Yi Chen, Jui-Yi Chen   +5 more
doaj   +1 more source